Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells
- 14 August 1992
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 186 (3), 1600-1606
- https://doi.org/10.1016/s0006-291x(05)81591-8
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusionInternational Journal of Cancer, 1992
- Synthesis and cytotoxic activity of C-glycosidic nicotinamide riboside analogsJournal of Medicinal Chemistry, 1992
- Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell LinesJNCI Journal of the National Cancer Institute, 1991
- Determination of thiazole-4-carboxamide adenine dinucleotide (TAD) levels in mononuclear cells of leukemic patients treated with tiazofurinBiochemical Pharmacology, 1991
- Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE AlgorithmJNCI Journal of the National Cancer Institute, 1989
- Biochemical mechanisms of resistance to tiazofurinAdvances in Enzyme Regulation, 1985
- Studies on the mechanism of action of tiazofurin metabolism to an analog of NAD with potent IMP dehydrogenase-inhibitory activityAdvances in Enzyme Regulation, 1983
- A straightforward radiometric technique for measuring IMP dehydrogenaseAnalytical Biochemistry, 1983
- Mechanism of resistance to the oncolytic C-nucleoside 2-β-D-ribofuranosylthiazole-4-carboxamide (NSC-286193)Biochemical Pharmacology, 1982
- Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-β-d-ribofuranosylthiazole-4-carboxamide NSC 286193)Biochemical Pharmacology, 1982